Baidu
map

Protein & Cell:武汉病毒所埃博拉病毒糖蛋白致病效应研究取得进展

2017-10-18 佚名 武汉病毒所

近日,中国科学院武汉病毒研究所王华林学科组在埃博拉病毒糖蛋白致病效应及其实验模型的研究中取得新进展,部分成果在线发表在Protein & Cell上。

近日,中国科学院武汉病毒研究所王华林学科组在埃博拉病毒糖蛋白致病效应及其实验模型的研究中取得新进展,部分成果在线发表在Protein & Cell上。

埃博拉病毒(Ebola virus,EBOV)是目前已知的对人类最致命的病毒之一,EBOV感染导致埃博拉病毒病(Ebola virus disease,EVD),临床上表现出过度的炎症反应及多器官功能的损伤,但其致病机理尚不清楚。EBOV可编码多种形式的糖蛋白(glycoprotein,GP),体外研究发现,EBOV囊膜糖蛋白GP1,2的表达诱导贴壁细胞变圆和脱落,暗示GP1,2除具有介导病毒入侵宿主细胞的功能外,似乎还有直接的致细胞病变效应;细胞水平的进一步研究发现,GP1,2刺突表面的一个重度O-糖基化的黏蛋白样区域(mucin-like region)是GP1,2导致细胞形变效应所必需的。此前对这些糖蛋白潜在致病效应的推测,只是基于细胞或组织培养物水平的初步研究,GP1,2及mucin-like糖蛋白部分的致病效应尚缺乏体内水平的直接证据;作为生物安全四级病毒,EBOV的致病机理研究受到高等级生物安全实验室等特定实验条件的限制。

研究中,王华林课题组构建了一系列腺病毒基因转移载体,并利用腺病毒基因转移技术,在生物安全二级实验室的实验条件下,系统地研究了EBOV包膜型mucin-like糖蛋白(Emuc)在细胞以及小鼠模型中表达的致病效应。研究人员验证了Emuc对贴壁细胞的致形变能力,又通过腺病毒基因转移、动物组织原位实时成像及组织病理学分析,发现Emuc包膜表达诱导了小鼠组织损伤并伴有显着的急性炎症反应,首次在体内水平证实了Emuc的致病效应,并对Emuc在动物模型中的致病性进行了大量细致分析。Emuc表达导致的急性炎症及组织损伤作用提示该蛋白可能在EBOV致病(包括引发过度炎症)的过程中扮演着重要角色,为EVD病理(特别是其炎症病理)的研究提供了重要线索。此外,该项研究也为进一步揭示Emuc等烈性病原体致病因子的致病效应及其分子机理,提供了重要且便捷的实验模型,此模型或可用于研发针对这些致病因子的特异性干预手段或治疗药物。

该研究得到了国家自然科学基金创新研究群体、国家重点研发计划以及研究所“一三五”规划等的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-11-28 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-20 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1870223, encodeId=fc4818e02236a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Dec 12 23:00:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650368, encodeId=17841650368a8, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Sat Sep 08 20:00:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960484, encodeId=205f196048448, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Nov 28 21:00:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296473, encodeId=598312964e310, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601934, encodeId=12a9160193480, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605208, encodeId=37f91605208c8, content=<a href='/topic/show?id=d88814e5699' target=_blank style='color:#2F92EE;'>#protein#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14756, encryptionId=d88814e5699, topicName=protein)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a45319348704, createdName=江川靖瑶, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620413, encodeId=a71c1620413aa, content=<a href='/topic/show?id=919f6333047' target=_blank style='color:#2F92EE;'>#武汉病毒所#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63330, encryptionId=919f6333047, topicName=武汉病毒所)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627240, encodeId=e6a6162e240dc, content=<a href='/topic/show?id=8ea0e6863a2' target=_blank style='color:#2F92EE;'>#糖蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76863, encryptionId=8ea0e6863a2, topicName=糖蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d6621112920, createdName=chentianping, createdTime=Fri Oct 20 05:00:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254224, encodeId=c6c32542243f, content=学习学习.继续关系, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Oct 19 07:50:16 CST 2017, time=2017-10-19, status=1, ipAttribution=)]
    2017-10-19 1dd8c52fm63(暂无匿称)

    学习学习.继续关系

    0

相关资讯

Cell Reports:科学家发现埃博拉病毒对免疫系统的早期影响

NIH的科学家使用一种新的早期埃博拉病毒(EBOV)感染的小鼠模型发现了免疫系统的早期免疫反应如何影响埃博拉病毒的发展。这个模型将有助于找到开发治疗EBOV感染药物的靶点。 来自美国NIH过敏和感染疾病研究所的科学家领导了这项研究,并与来自华盛顿大学和哥伦比亚大学的科学家一起合作完成。 科学家们分析了宿主细胞驱使免疫系统应对EBOV感染的信号通路及免疫系统由此产生的免疫反应。他们主

高福院士:“小”世界里做大事

约到高福很难,在中国科学院微生物研究所,熟悉他的人都说,高福是所里最忙、最辛苦的人。 翻开高福的简历,中科院院士、中国疾病预防控制中心副主任、中科院微生物研究所病原微生物与免疫学重点实验室主任、国科大医学院院长、中华医学会副会长……数十个头衔加身的他,恨不得24个小时都拿来工作。 可他却笑笑说,自己偶尔还能跑到电影院,去看部热门大片。 如此游刃有余,他是怎么做到的? 留在非洲的秘密

中国生命科学领域十大进展:婴幼儿白内障全新治疗策略

3 月 16 日消息,中国科协生命科学学会联合体组织 18 个成员学会推荐,经生命科学领域同行专家审核与评选,现向社会公布 2016 年度“中国生命科学领域十大进展”评选结果(排名不分先后)。

CDE召开专家咨询会,加快「重组埃博拉病毒病疫苗」上市进程

为加快重组埃博拉病毒病疫苗上市审评进程,探讨在Ⅲ期临床试验无法开展的情况下,针对重大公共卫生问题研发的应急类疫苗注册上市的路径及技术评价标准,保障审评的科学性和严谨性,药审中心近日召开重组埃博拉病毒病疫苗专家咨询会议,针对疫苗审评过程中的重大技术问题公开咨询专家意见。

PLoS Med:Xpert——埃博拉病毒检测新方法!

 埃博拉病毒在西非国家大肆传播,野外实验室检测埃博拉病毒依赖于复杂的、多步骤的实时逆转录PCR检测;一种精确的RT-PCR检测将减少检测病毒的时间,并且有可能增加检测效率。来自英国、美国、塞拉利昂等国的科研人员评价了一中检测埃博拉病毒的方法Cepheid GeneXpert的性能。这种方法通过静脉穿刺获得全血(WB)和口腔粘膜(BS)测试样本。 此项研究在公共卫生英格兰EVD检

Nature:埃博拉疫苗研究经费掩盖了其他疾病经费不足

摘要 : 根据澳大利亚悉尼一家健康政策分析公司“政策治疗研究”的年度G-FINDER(全球被忽视疾病创新基金 )投资报告,用于被忽视疾病(包括结核病、艾滋病病毒/艾滋病和疟疾等)研究的全球资金正处于2007年以来的最低水平。根据澳大利亚悉尼一家健康政策分析公司“政策治疗研究”的年度G-FINDER(全球被忽视疾病创新基金 )投资报告,用于被忽视疾病(包括结核病、艾滋病病毒/艾滋病和疟疾等)研究的全

Baidu
map
Baidu
map
Baidu
map